Health and Healthcare
Deciphering Medarex Earnings (MEDX)
Published:
Last Updated:
Some traders might bother peering at the losses on Medarex (NASDAQ:MEDX), but all we are looking at for the time being is the forward study data and the company’s use of cash and burn rates. When you see the explanation and the stock options activity you’ll understand why. Here is all that matters, to 24/7 Wall St. anyway:
This "ipilimumab monotherapy studies in second-line metastatic melanoma patients" is the program with Bristol-Myers Squibb (NYSE:BMY) that has options traders making huge bets since this is still a relatively untreated killer with blockbuster potential. This "before the end of this year" statement leaves the NOV and DEC options expiration dates as still having a chance of seeing the news, but the true tally is loaded up in the JANUARY-2008 options contracts:
Recent key stories on Medarex:
Jon C. Ogg
October 31, 2007
Jon Ogg can be reached at [email protected]; he produces the Special Situation Investing Newsletter and does not own securities in the companies he covers.
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the
advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.